Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...
Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results